Sharma, M. R., Johnson, M. L., Puzanov, I., Sznol, M., Mckean, M., Gainor, J. F., Spira, A., Henick, B., Tolcher, A. W., Chen, C. T., El-Khoueiry, A., Broderick, J., Peng, L., Che, J., Cao, L., Wilson, D., Lathers, D., Horak, C., Feltquate, D., & Luke, J. J. (2024). 758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors. Regular and Young Investigator Award Abstracts, A862–A862. https://doi.org/10.1136/jitc-2024-sitc2024.0758